NJK14047 inhibits p38 MAPK and prevents the differentiation of naive T-cells into Th1 and Th17 cells, thereby ameliorating collagen-induced rheumatoid arthritis and Imiquimod-induced psoriasis in mice [1].

NJK14047 (3-10 μM) suppresses the expression of inflammatory cytokines IL-1β, TNF-α, IL-6, IL-17A, RANKL, and MMP-3 in SW982 synovial cells stimulated by lipopolysaccharide [1]. NJK14047 (3-10 μM) also inhibits the differentiation of naive CD4+ T cells into Th1, Th2, and Th17 cells in a dose-dependent manner [1].

In the collagen-induced arthritis (CIA) model in DBA-1J mice and the imiquimod-induced psoriasis (IIP) model in BALB/c mice, the compound NJK14047 (2.5 mg/kg, intraperitoneal injection, administered over 7 days for IIP in BALB/c mice and 21 days for CIA in DBA-1J mice) significantly ameliorated the pathological symptoms of rheumatoid arthritis and psoriasis. This chemical effectively inhibited the expression of Th1, Th2, Th17, and Treg cell cytokines, mitigating arthritis, cartilage damage, inflammation, synovial hyperplasia, bone erosion, and tumor formation caused by CIA. It also improved the hyperproliferation of keratinocytes associated with imiquimod-induced psoriasis. [1]